Defining a target product profile for antimicrobials to treat severe paediatric bacterial enteric infections in low- and medium-income countries, caused by E. coli , Shigella , Salmonella and Campylobacter species
JAC-Antimicrobial Resistance · 02.07.2026 · 8 (4)
DOI: 10.1093/jacamr/dlag128 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 10.07.2026. Verfasst von Marie Attwood und 11 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Centre for Antimicrobial Research & Evaluation (BCARE), North Bristol NHS Trust, Bristol, UK. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, Innovative Medicines Initiative 2 Joint Undertaking, European Union’s Horizon 2020.
Abstract (Originalsprache)
Paediatric diarrhoea is associated with 500 000 childhood deaths each year in low- and middle-income countries (LMICs). Enteropathogenic Escherichia coli, Shigella spp., Salmonella spp. and Campylobacter spp. are among the most common causative bacterial pathogens, however, their burden and rates of antimicrobial resistance (AMR) are poorly quantified. Current treatment typically involves oral and intravenous rehydration fluids, nutritional support for malnourished children, antibiotics for severe bacterial infections, antiemetic and anti-diarrheal medications, and analgesics. The World Health Organization recommends first-line empirical treatment of ciprofloxacin, with alternatives of third-generation cephalosporins or azithromycin. At present, no new antibacterials are in development specifically to treat paediatric diarrhoea. Target product profiles (TPPs) are used typically in drug development and describe the desired characteristics of a new therapeutic. In this paper, we aim to define a TPP for the development of novel antimicrobials for the treatment of severe paediatric diarrhoea in LMICs. Oral and intravenous formulations are preferable. Safety, tolerability, resolution of clinical signs and symptoms must be equivalent or better than standard of care (SoC) therapy. Interactions with commonly used therapies such as zinc, milk and traditional cures should be minimal. In addition, formulations should be stable at elevated temperatures and for extended periods of time to facilitate access and distribution across LMICs.
Autor:innen und Institutionen
- Bristol Centre for Antimicrobial Research & Evaluation (BCARE), North Bristol NHS Trust, Bristol, UK.
- Afrocab, Treatment Access Partnership (AFROCAB), Lusaka, Zambia.
- CARB-X, Boston University, Boston, MA 02215, USA.
- AMR Department, World Health Organization (WHO), Geneva, Switzerland.
- Senior Clinical Director, Clinton Health Access Initiative, Dorchester Avenue, Boston, MA, USA.
- Global Health Innovation, Lygature, Jaarbeursplein 6, Utrecht 3521 AL, the Netherlands.
ORCID-Profile: Marie Attwood, Joseph Harwell, Dorothy Yeboah-Manu
Förderung
- World Health Organization
- Innovative Medicines Initiative 2 Joint Undertaking
- European Union’s Horizon 2020
Zitieren
APA
Attwood, M., Choola, T., Duffy, E., Gigante, V., Harwell, J., Hulshof, L. A., Kariuki, S. M., Mercer, D. K., Orrling, K. M., Paterson, D., Yeboah-Manu, D., & MacGowan, A. (2026). Defining a target product profile for antimicrobials to treat severe paediatric bacterial enteric infections in low- and medium-income countries, caused by E. coli , Shigella , Salmonella and Campylobacter species. JAC-Antimicrobial Resistance, 8(4). https://doi.org/10.1093/jacamr/dlag128
Vancouver
Attwood M, Choola T, Duffy E, Gigante V, Harwell J, Hulshof LA, et al. Defining a target product profile for antimicrobials to treat severe paediatric bacterial enteric infections in low- and medium-income countries, caused by E. coli , Shigella , Salmonella and Campylobacter species. JAC-Antimicrobial Resistance. 2026;8(4). doi:10.1093/jacamr/dlag128
BibTeX
@article{Attwood2026,
author = {Attwood, Marie and Choola, Tamara and Duffy, Erin and Gigante, Valeria and Harwell, Joseph and Hulshof, Lianne A and Kariuki, Samuel M and Mercer, Derry K and Orrling, Kristina M and Paterson, David and Yeboah-Manu, Dorothy and MacGowan, Alasdair},
title = {Defining a target product profile for antimicrobials to treat severe paediatric bacterial enteric infections in low- and medium-income countries, caused by E. coli , Shigella , Salmonella and Campylobacter species},
journal = {JAC-Antimicrobial Resistance},
year = {2026},
volume = {8},
number = {4},
doi = {10.1093/jacamr/dlag128}
}
EUVIMED